Edwards Lifesciences (NYSE:EW) Releases Q1 2026 Earnings Guidance

Edwards Lifesciences (NYSE:EW) updated its first quarter 2026 earnings guidance on Tuesday. The company provided EPS guidance of 0.700-0.760 for the period, compared to the consensus EPS estimate of 0.690. The company issued revenue guidance of $1.6 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Raymond James Financial raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective for the company in a research note on Monday, November 3rd. Stifel Nicolaus set a $110.00 price target on Edwards Lifesciences and gave the company a “buy” rating in a research report on Tuesday, January 20th. Citigroup reiterated a “buy” rating and issued a $101.00 price objective (up previously from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. Royal Bank Of Canada boosted their target price on Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Friday, December 5th. Finally, Barclays restated an “overweight” rating and set a $104.00 target price (up previously from $103.00) on shares of Edwards Lifesciences in a report on Monday, January 12th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $96.14.

Edwards Lifesciences Stock Down 3.5%

EW traded down $2.74 during midday trading on Thursday, reaching $76.59. The company’s stock had a trading volume of 1,909,477 shares, compared to its average volume of 4,358,773. The stock’s 50-day moving average is $83.73 and its 200-day moving average is $81.13. Edwards Lifesciences has a 1 year low of $65.94 and a 1 year high of $87.89. The firm has a market capitalization of $44.45 billion, a price-to-earnings ratio of 41.89, a PEG ratio of 2.98 and a beta of 0.94. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The company had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm’s quarterly revenue was up 13.3% on a year-over-year basis. During the same period last year, the business earned $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, research analysts expect that Edwards Lifesciences will post 2.45 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 11,340 shares of the firm’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $85.66, for a total value of $971,384.40. Following the transaction, the vice president directly owned 31,870 shares of the company’s stock, valued at approximately $2,729,984.20. This trade represents a 26.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the sale, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,885,571.40. The trade was a 4.43% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 43,804 shares of company stock valued at $3,699,082. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences News Summary

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Company guidance and demand outlook: Management forecasted 2026 profit above Street estimates and issued Q1 2026 EPS guidance (0.700–0.760) that sits above consensus — signaling confidence in continued demand for heart valves and devices. Edwards forecasts 2026 profit above estimates
• Positive Sentiment: Revenue growth driven by core products: Q4 sales grew ~13.3% YoY with strong transcatheter aortic valve replacement (TAVR) and >40% growth in TMTT, supporting the company’s 2026 sales growth outlook. Q4 results and product growth
• Positive Sentiment: Analyst backing and higher targets: Multiple firms reaffirmed Buy/Overweight ratings and raised targets (Wells Fargo raised its target to $100; BTIG and others kept $103 targets), which supports medium-term upside expectations. Analyst rating summaries
• Neutral Sentiment: Options/strategies commentary: Market commentary suggests the post-earnings volatility and perceived “poor start” provide contrarian options opportunities for income/hedge trades rather than a fundamental signal. Options strategy piece
• Neutral Sentiment: Earnings call transcript available: Investors can review management commentary and Q&A for color on margin drivers and product cadence. Earnings call transcript
• Negative Sentiment: EPS and profit pressure: Adjusted EPS missed estimates and reported operating profit and net income showed substantive year-over-year declines in some reported metrics, highlighting margin stress despite revenue gains. Earnings miss and margin note
• Negative Sentiment: Cash-flow, profitability and insider selling: Third‑party summaries flagged weaker operating cash flow, sharp declines in net income on a GAAP basis, and multiple insider sales over recent months — factors that can undermine near-term sentiment. Detailed financials and insider activity

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. BOKF NA raised its position in shares of Edwards Lifesciences by 9.8% during the third quarter. BOKF NA now owns 2,214 shares of the medical research company’s stock valued at $172,000 after buying an additional 198 shares during the last quarter. Larson Financial Group LLC grew its position in shares of Edwards Lifesciences by 8.3% during the third quarter. Larson Financial Group LLC now owns 2,948 shares of the medical research company’s stock valued at $229,000 after purchasing an additional 227 shares in the last quarter. Elevation Point Wealth Partners LLC increased its holdings in shares of Edwards Lifesciences by 7.0% in the third quarter. Elevation Point Wealth Partners LLC now owns 4,071 shares of the medical research company’s stock worth $317,000 after purchasing an additional 266 shares during the last quarter. Dorsey & Whitney Trust CO LLC lifted its position in shares of Edwards Lifesciences by 6.0% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 4,797 shares of the medical research company’s stock worth $409,000 after buying an additional 272 shares in the last quarter. Finally, Rakuten Securities Inc. boosted its stake in Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after buying an additional 302 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.